Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS ...

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression ...

(A) Presence of PD-1, its ligands PD-L1 and PD-L2, and the phosphatases SHP-1, SHP-2, and SHP-2-like (SHP-2L) in representative jawed vertebrates, including sharks, ray-finned fish, amphibians, and ...

Distinct glycolysis-related molecular subtypes in GC were identified using TCGA and GEO datasets. CLDN9 was identified as a key gene associated with the glycolytic subtype and prognosis of GC. CLDN9 ...

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients FDA priority ...